Pluri (PLUR) Cash from Investing Activities (2010 - 2025)
Pluri (PLUR) reported Cash from Investing Activities of $2.7 million for Q4 2025, down 69.25% year-over-year from $8.6 million in Q4 2024, and down 30.96% quarter-over-quarter from $3.8 million in Q3 2025.
Pluri (PLUR) Cash from Investing Activities (2010 - 2025) Analysis & Trends
Pluri (PLUR) has 16 years of Cash from Investing Activities data on file, last reported at $2.7 million in Q4 2025.
- Cash from Investing Activities for Q4 2025 came in at $2.7 million, down 69.25% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.3 million (down 47.45% YoY), and the FY2025 annual result was $8.0 million, down 24.17% from the prior year.
- Cash from Investing Activities declined to $2.7 million in Q4 2025 per PLUR's latest filing, from $3.8 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $14.3 million in Q4 2021 and troughed at -$23.8 million in Q1 2021.
- A 5-year average of $1.4 million and a median of $3.4 million in 2025 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2021 and 2025: Cash from Investing Activities tumbled 3635.31% in 2021, then surged 558.12% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at $14.3 million in 2021, then slumped by 95.33% to $669000.0 in 2022, then soared by 485.8% to $3.9 million in 2023, then soared by 120.59% to $8.6 million in 2024, then tumbled by 69.25% to $2.7 million in 2025.
- Business Quant data shows PLUR's Cash from Investing Activities at $2.7 million in Q4 2025, $3.8 million in Q3 2025, and $3.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 579,519.10 |
| 10 | Pluri | 21.85 Mn | 22.34 Mn | 86,000.00 | 2.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.66 Mn |
| Dec 31, 2025 | 2.66 Mn |
| Sep 30, 2025 | 3.85 Mn |
| Sep 30, 2025 | 3.85 Mn |
| Jun 30, 2025 | 3.03 Mn |
| Jun 30, 2025 | 3.03 Mn |
| Mar 31, 2025 | -4.23 Mn |
| Mar 31, 2025 | -4.23 Mn |
| Dec 31, 2024 | 8.65 Mn |
| Dec 31, 2024 | 8.65 Mn |
| Sep 30, 2024 | 585,000.00 |
| Sep 30, 2024 | 585,000.00 |
| Jun 30, 2024 | -4.81 Mn |
| Jun 30, 2024 | -4.81 Mn |
| Mar 31, 2024 | 5.67 Mn |
| Mar 31, 2024 | 5.67 Mn |
| Dec 31, 2023 | 3.92 Mn |
| Dec 31, 2023 | 3.92 Mn |
| Sep 30, 2023 | 5.80 Mn |
| Sep 30, 2023 | 5.80 Mn |